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S U M M A R Y
Background: Trends in hepatitis B virus (HBV) infection are important in evaluating the effectiveness of
the recommended routine vaccination of infants and adolescents.
Methods: The prevalence of HBV infection was determined in a representative sample of the Korea
National Health and Nutrition Examination Survey for 1998 (n = 9771) and 2009 (n = 8304). Participants
aged 10 years were tested for the hepatitis B surface antigen (HBsAg).
Results: The overall age-adjusted HBsAg seroprevalence was 4.6% (95% conﬁdence interval (CI) 4.2–5.0%)
in 1998 and 3.2% (95% CI 2.9–3.6%) in 2009, which represents a relative decrease of 30.4% between the
two survey populations (p < 0.05). The prevalence of HBsAg decreased among persons 10–19 years of
age (from 2.2% to 0.3%), 20–29 years of age (from 5.4% to 2.5%), 30–39 years of age (from 6.1% to 4.3%),
40–49 years of age (from 5.1% to 4.7%), and 50–59 years of age (from 5.3% to 3.7%). HBsAg seroprevalence
did not decrease among persons 60 years of age (2.7% vs. 2.9%).
Conclusions: These data show a decline in HBsAg seroprevalence, primarily due to the dramatic decrease
in adolescents and younger adults.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Hepatitis B virus (HBV) infection remains a major public health
burden in many parts of the world, especially in high prevalence
areas such as the Asia-Paciﬁc region. It is estimated that more than
2 billion people worldwide have been infected with HBV. Of these
people, approximately 360 million individuals (6% of the world
population) are chronically infected and are at risk of serious
illness and death, mainly from liver cirrhosis or hepatocellular
carcinoma. Mathematical modeling for the year 2000 estimated
the yearly number of deaths from HBV-related diseases to be
approximately 600 000 worldwide.1 Because, HBV is most
commonly spread from mother to child at birth or from person
to person in early childhood in highly endemic areas,2–4 universal
infant vaccination is the single most effective measure in
preventing the transmission of HBV. In 1992, the World Health
Organization recommended that all countries implement univer-
sal HBV vaccination by 1997.5 Most countries have incorporated
universal HBV vaccination into their national infant immunization
programs. As of 2008, 177 (92%) of the 193 World Health
Organization member states had initiated HBV vaccination
programs.6 Before the introduction of the HBV vaccine in Korea,
the prevalence of HBV was up to 10% in the general population.7* Tel.: +82 51 797 0200; fax: +82 51 797 3009.
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http://dx.doi.org/10.1016/j.ijid.2012.05.1019The ﬁrst national HBV vaccination program began in 1985 for
newborn infants whose mothers were HBV surface antigen
(HBsAg) carriers, and the national universal vaccination program
was launched in 1995.
As the majority of people infected with HBV do not develop
clinical disease, seroepidemiological studies provide a more
comprehensive picture of the distribution of this infection
compared to acute disease surveillance. Trends in HBV infection
are important in evaluating the effectiveness of the recommended
routine vaccination of infants and adolescents along with adults at
high risk of infection. To assess Korean trends in the prevalence of
HBV and to provide the ﬁrst nationally representative analysis of
the impact of the nationwide universal vaccination program, we
compared the prevalence of HBV infection among the Korea
National Health and Nutrition Examination Survey (KNHANES)
participants in 1998 to the prevalence among participants in the
2009 survey.
2. Methods
2.1. Sample population
KNHANES is a series of cross-sectional, national health and
nutrition surveys designed to provide representative prevalence
estimates for a variety of health measures and conditions and is
conducted by the Korea Centers for Disease Control and Preven-
tion. The survey design is a complex, stratiﬁed, multi-stageses. Published by Elsevier Ltd. All rights reserved.
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population. The procedures used to select the sample and conduct
the interview and examination have been speciﬁed elsewhere.8
The survey included an interview to obtain information on health
history, health behaviors, and risk factors, and a subsequent health
examination was performed at a mobile examination center.
Our analyses include data from 1998 (KNHANES 1998) and
2009 (KNHANES 2009). Starting with KNHANES 1998, serum
samples from participants aged 10 years were tested for HBsAg
(electrochemiluminescence immunoassay; Roche Diagnostics,
Switzerland), but antibodies to hepatitis B core antigen (anti-
HB) and hepatitis B surface antigen (anti-HB) were not included in
the KNHANES protocol. In KNHANES 1998, 10 876 individuals aged
10 years were sampled, and 9771 individuals participated in the
seroepidemiological survey; the response rate was 89.8%. In
KNHANES 2009, 9231 individuals aged 10 years were sampled,
and 8304 individuals completed the survey; the response rate was
90%. Sample weights were used to account for the differential
probabilities of selection and nonresponse9 and were included in
the estimation process for all analyses. Prevalence estimates were
age-adjusted by the direct method, using the age groups from the
2005 Korean Census population for comparisons across subgroups
and between surveys. Informed consent was obtained from all
participants, and the Institutional Review Board of the Korea
Centers for Disease Control and Prevention approved the protocol.
2.2. Data analyses
Demographic variables (age, sex, and area of residence (urban
or rural)), education, marital status, and family income were
considered as covariates. Monthly family income was calculated by
household income divided by the number of household members
and grouped into 4 categories. Weighted frequencies and cross-
tabulations were computed to represent the Korean civilian,Table 1
Weighted hepatitis B virus surface antigen seroprevalence among persons aged 10 yea
Sample size Prevalence, % (
Overall 8304 3.2 (2.8–3.6)
Sex
Female 4580 2.9 (2.4–3.4) 
Male 3724 3.5 (3.0–4.2) 
Age group, years
10–19 1203 0.3 (0.09–0.8)b
20–29 930 2.5 (1.8–3.5) 
30–39 1385 4.3 (3.5–5.5) 
40–49 1475 4.7 (3.8–5.9) 
50–59 1218 3.7 (2.7–4.9) 
60 2093 2.9 (2.2–4.0) 
Marital status (participants aged 20 years)
Married/cohabiting 5125 4.0 (3.5–4.6) 
Divorced/separated/widowed 977 3.5 (2.4–5.0) 
Never married 999 2.7 (2.0–3.7) 
Education (participants aged 20 years)
Less than high school 2722 3.2 (2.5–4.0) 
High school 2448 3.4 (2.8–4.2) 
College or higher 1881 4.5 (3.7–5.4) 
Missing 50
Family income
Low 1618 3.2 (2.4–4.3) 
Mid-low 1895 3.2 (2.5–4.1) 
Mid-high 2350 2.7 (2.2–3.5) 
High 2356 3.8 (3.1–4.6) 
Missing 85
Area of residence
Urban 6282 3.2 (2.8–3.6) 
Rural 2022 3.4 (2.6–4.4) 
KNHANES, Korea National Health and Nutrition Examination Survey; CI, conﬁdence in
a Adjusted for sex, age, marital status, education attainment, family income, and are
b Estimate based on <10 individuals with positive samples.non-institutionalized population and to account for over-sampling
and non-response to the interview and medical examination.
Sample weights were included in all estimations. Multiple logistic
regression of the KNHANES 2009 dataset was used to estimate the
odds ratios (OR) of HBsAg seroprevalence while controlling for the
covariates listed above. Prevalence estimates of HBsAg for some
subgroups, as noted in the tables, are based on a small number of
persons with positive results and may be unstable. Differences in
HBsAg seroprevalence between the surveys were considered to be
statistically signiﬁcant if the two-sampled t-test had a p-value of
less than 0.05.10 Statistical hypotheses were tested at the p < 0.05
level of signiﬁcance.
3. Results
In 2009, the seroprevalence of HBsAg among participants aged
10 years was 3.2% (95% conﬁdence interval (CI) 2.8–3.6%; Table
1). The seroprevalence was higher among males than among
females (3.5% vs. 2.9%; p < 0.05). The prevalence of HBsAg was
considerably lower among teenagers (0.3%) than in the other age
groups. Prevalence increased rapidly with increasing age, peaking
in the 40–49 years age group (4.7%), and decreased in the 50–59
years age group (3.7%) and among persons aged 60 years (2.9%).
In comparison with persons who were married, those who had
never been married had a decreased prevalence of infection.
However, there was no difference between groups according to
level of education, family income, or area of residence.
Using the 2005 Korean Census civilian, non-institutionalized
population aged 10 years as the standard, the overall age-
adjusted HBsAg seroprevalence was 4.6% (95% CI 4.2–5.0%) in 1998
and 3.2% (95% CI 2.9–3.6%) in 2009, a relative decrease of 30.4%
between the two surveys (p < 0.05; Table 2). There was a 28.8%
decrease in males and a 30% decrease in females, and these
decreases were statistically signiﬁcant. In addition, seroprevalencers and older in KNHANES 2009
95% CI) Unadjusted OR (95% CI) Adjusted ORa (95% CI)
1 1
1.36 (1.06–1.74) 1.30 (1.01–1.67)
1 1
9.36 (2.96–29.6) 8.05 (2.48–26.17)
16.53 (5.37–50.91) 12.80 (3.83–42.77)
17.98 (5.85–55.23) 14.22 (4.25–47.60)
13.71 (4.39–42.82) 11.14 (3.31–37.53)
10.88 (3.46–34.16) 8.87 (2.62–30.04)
1 1
0.85 (0.57–1.28) 1.05 (0.67–1.65)
0.67 (0.47–0.94) 0.58 (0.38–0.88)
1 1
1.08 (0.79–1.47) 1.01 (0.68–1.48)
1.41 (1.03–1.93) 1.26 (0.84–1.90)
1 1
1.00 (0.67–1.50) 0.94 (0.61–1.44)
0.86 (0.58–1.27) 0.76 (0.50–1.17)
1.22 (0.84–1.76) 0.98 (0.65–1.48)
1 1
1.05 (0.77–1.43) 1.06 (0.77–1.45)
terval; OR, odds ratio.
a of residence.
Table 2
Changes in weighted hepatitis B virus surface antigen seroprevalence among persons aged 10 years and older between 1998 and 2009
1998 2009
Sample size Prevalence, % (95% CI) Sample size Prevalence, % (95% CI) Difference (95% CI)
Overalla 9771 4.6 (4.2–5.0) 8304 3.2 (2.9–3.6) 1.4 (1.3–1.5)b
Age group, years
10–19 1809 2.2 (1.7–2.9) 1203 0.3 (0.09–0.8)c 1.9 (1.8–2.0)b
20–29 1493 5.4 (4.6–6.4) 930 2.5 (1.8–3.5) 2.9 (2.7–3.1)b
30–39 1968 6.1 (5.2–7.0) 1385 4.3 (3.5–5.5) 1.8 (1.5–2.1)b
40–49 1630 5.1 (4.3–6.1) 1475 4.7 (3.8–5.9) 0.4 (0.1–0.7)b
50–59 1260 5.3 (4.3–6.6) 1218 3.7 (2.7–4.9) 1.6 (1.3–1.9)b
60 1611 2.7 (2.0–3.6) 2093 2.9 (2.2–4.0) 0.2 (0–0.4)
Sex by age group, years
Male
All agesa 5.2 (4.8–5.7) 3724 3.7 (3.1–4.3) 1.5 (1.3–1.7)b
10–19 917 1.9 (1.3–2.8) 624 0.3 (0.1–1.2)c 1.6 (1.5–1.7)b
20–29 659 6.9 (5.6–8.6) 432 2.9 (1.9–4.5) 4.0 (3.6–4.4)b
30–39 923 6.2 (5.0–7.5) 587 4.8 (3.6–6.5) 1.4 (0.9–1.9)b
40–49 775 6.3 (5.1–7.9) 631 5.8 (4.4–7.6) 0.5 (0–1.0)
50–59 575 6.4 (4.8–8.4) 540 4.4 (3.1–6.3) 2.0 (1.4–2.6)b
60 665 2.6 (1.7–4.1) 910 2.6 (1.6–4.2) 0
Female
All agesa 4.0 (3.6–4.4) 4580 2.8 (2.3–3.3) 1.2 (1.1–1.3)b
10–19 892 2.5 (1.8–3.5) 579 0.2 (0.04–1.0)c 2.3 (2.2–2.4)b
20–29 834 4.1 (3.1–5.3) 498 2.0 (1.2–3.4)c 2.1 (1.8–2.4)b
30–39 1045 6.0 (4.9–7.4) 798 3.8 (2.7–5.4) 2.2 (1.8–2.6)b
40–49 855 3.9 (2.9–5.2) 844 3.7 (2.6–5.2) 0.2 (-0.1–0.5)
50–59 685 4.2 (3.0–5.8) 678 2.8 (1.8–4.5) 1.4 (1.1–1.7)b
60 946 2.8 (2.0–4.0) 1183 3.1 (2.1–4.6) 0.3 (0–0.6)
CI, conﬁdence interval.
a Age-adjusted using the 2005 Korean Census civilian, non-institutionalized population as the standard.
b p < 0.05 determined by t-test evaluating difference across surveys.
c Estimate based on < 10 individuals with positive samples.
S.H. Park / International Journal of Infectious Diseases 16 (2012) e669–e672 e671of HBsAg decreased signiﬁcantly in all age groups, except in
participants aged 60 years. In particular, the prevalence
decreased dramatically in teenagers with a relative decrease of
86.4%, and in the 20–29 years age group with a relative decrease of
53.7% (Figure 1).
4. Discussion
The KNHANES is the only population-based survey that
provides nationally representative estimates of the prevalence –
and, therefore, the lifetime risk – of HBV infection. The two surveys
described here demonstrate a decrease in the seroprevalence of
HBsAg in Korea of 30% in persons aged 10 years over the 11-yearFigure 1. Hepatitis B virus surface antigen seroprevalence by age in 1998 and 2009
(the percentage of persons is weighted; *age-adjusted using the 2005 Korean
Census civilian, non-institutionalized population as the standard).interval. The change in HBsAg seroprevalence is consistent with
data from previous reports from around the world, which have
shown the prevalence of HBsAg or HBV infection to have declined
signiﬁcantly since the introduction of hepatitis B vaccination
programs, especially in children and adolescents.11–13
Because HBV is a lifetime infection, any increases or decreases
in HBsAg seroprevalence are expected to be seen ﬁrst in younger
persons. In adolescents and younger adults, HBsAg seroprevalence
is a cumulative measure of recent exposures. The most dramatic
ﬁnding of this study is the decrease in HBsAg prevalence among
teenagers and the 20–29 years age group. The HBsAg prevalence
among participants aged 10–19 and 20–29 years decreased by 86%
and 54%, respectively. The decrease in HBsAg seroprevalence in
these groups provides biological evidence supporting ﬁndings
from a national survey that showed approximately 79.7% of
neonates born after 1983 and 98.9% of neonates born after 1990
received the HBV vaccine.14 The ﬁrst domestic plasma-derived
HBV vaccine became available in Korea in 1982, and HBV
vaccination has been recommended for all neonates since 1983.
A national HBV vaccination program for school-aged children was
launched in Korea in 1988, and the HBV vaccination was
incorporated into the national vaccination guidelines in 1991.15
The dramatic decline in HBV infection that was found in this study
may be related to these immunization efforts.
In addition, a decrease in HBsAg seroprevalence in adults is not
unexpected, due to other possible contributing factors, such as the
policy that reduces horizontal transmission in the home and safer
injection practices that reduce nosocomial transmission. The HBV
vaccine is also recommended for high-risk adult groups (e.g.,
healthcare workers, drug users, people who live with chronically
infected persons, chronic hemodialysis patients, HIV-infected
patients, and other immunocompromised persons). Despite the
substantial progress in preventing HBV infection in adolescents,
this study conﬁrms the ongoing high prevalence of HBV infection
among adults and the consequent high risks of HBV transmission
S.H. Park / International Journal of Infectious Diseases 16 (2012) e669–e672e672and chronic sequelae. This ﬁnding emphasizes the need to improve
screening programs and other efforts to identify chronically
infected persons, most of whom remain asymptomatic until they
develop cirrhosis or end-stage liver disease. Programs to prevent
the long-term consequences of HBV infection, including screening
and antiviral drug treatment, should be developed and expanded
to reach those at risk of developing cirrhosis and liver cancer.16
A major strength of the present study is that the data are
representative of the Korean population and were collected using
standardized measurements. However, there are also a number of
limitations. Because anti-HBs and anti-HBc tests were not included
in the KNHANES protocol, only current HBV infections could be
examined, not past HBV infection or vaccine-induced immunity.
Also, HBV vaccinations and histories of HBV disease are not
recorded in KNHANES; therefore, we do not know the effect of
vaccination on HBsAg seropositivity. Another limitation is that the
survey participants were sampled only from the non-institution-
alized Korean population, excluding incarcerated persons and
homeless persons, among whom HBV prevalence is known to be
high.17 Therefore, the overall HBsAg prevalence is underestimated.
In conclusion, these ﬁndings from a nationally representative
sample provide the most up-to-date prevalence estimates of HBsAg
seropositivity in the Korean population. The HBsAg seroprevalence
in persons aged 10 years in 2009 was 3.2%, which is a signiﬁcant
decrease from 4.6% in 1998, though this prevalence still illustrates
the remaining high burden of HBV infection. The decreased HBsAg
seroprevalence was primarily due to a dramatic decline in
adolescents and younger adults. The ability to monitor HBsAg
seroprevalence using KNHANES is important for improving HBV
prevention strategies, such as those related to ongoing HBV
vaccinations. As we continue to report decreases in HBV infection,
especially in younger persons, we will see a concomitant decrease in
HBV-related morbidity and associated medical costs.
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